Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Non-Small Cell Lung Cancer (NSCLC) Market Covering 2025–2034?
The non-small cell lung cancer (nsclc) market has seen a rapid expansion in its size over recent years. It is projected to increase from $20.1 billion in 2024 to $22.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.1%. The growth observed in prior periods can be attributed to the progression of immunotherapy, genomic profiling and precision medicine, the broader scope of clinical trials, and initiatives aimed at smoking cessation.
The non-small cell lung cancer (nsclc) market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $32.88 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.4%. This projected growth during the forecast period is attributable to several factors, including the emergence of combination therapies, the integration of artificial intelligence (AI), the broader availability of personalized vaccines, worldwide research collaborations, and an increased focus on patient-centric care. Key trends expected within the forecast timeframe encompass the incorporation of telemedicine into oncology practices, advancements in liquid biopsy technologies, further developments in diagnostic techniques, the increasing adoption of minimally invasive surgical procedures, and the continued use of immune checkpoint inhibitors.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Non-Small Cell Lung Cancer (NSCLC) Industry?
The non-small cell lung cancer (NSCLC) market is projected to expand due to the rising prevalence of tobacco use. Tobacco consumption involves individuals utilizing tobacco products, often through smoking, chewing, or snuffing, which introduces nicotine and various other chemicals into their systems. Multiple carcinogens present in tobacco smoke can harm the DNA (deoxyribonucleic acid) within lung cells, thereby causing mutations and the unchecked proliferation of cancerous cells, specifically non-small-cell lung cancer (NSCLC). As an illustration, data from October 2024, derived from the 2024 National Youth Tobacco Survey released by the US Food and Drug Administration (USFDA), a federal agency in the US, revealed that 1.1% of all students, totaling around 2.25 million, indicated current tobacco product use. This included 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (around 640,000) who reported tobacco usage. Furthermore, 2.8% of students (about 760,000) reported current use of any combustible tobacco product, and 3.0% (approximately 840,000) reported using multiple tobacco products. Consequently, the increasing rate of tobacco consumption is a primary factor fueling the expansion of the non-small cell lung cancer (NSCLC) market.
What Are The Major Segments Identified In The Non-Small Cell Lung Cancer (NSCLC) Market?
The non-small cell lung cancer (nsclc)market covered in this report is segmented –
1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma; Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma; Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma; Sarcomatoid Carcinoma
What Are The Major Trends Driving The Growth Of The Non-Small Cell Lung Cancer (NSCLC) Market?
Leading firms in the non-small cell lung cancer (NSCLC) market are prioritizing the creation of diverse therapeutic approaches, including monotherapy treatments, to secure a competitive advantage. Monotherapy refers to employing only one drug or therapeutic method to address a medical ailment, meaning it relies on a singular approach instead of combining several interventions. A notable example occurred in June 2022 when Novartis AG, a pharmaceutical company based in Switzerland, obtained approval from the European Commission (EC), a governing body situated in Belgium, for Tabrecta (capmatinib) to treat adult patients afflicted with advanced non-small cell lung cancer featuring METex14 skipping. This provides an innovative targeted therapy choice for European patients who have undergone previous treatments and suffer from advanced non-small cell lung cancer (NSCLC) with mutations leading to MET exon 14 (METex14) skipping. This particular treatment is recognized as the most favored targeted therapy for advanced non-small cell lung cancer (NSCLC) characterized by modifications that induce METex14 skipping.
Which Key Players Are Driving Competition In The Non-Small Cell Lung Cancer (NSCLC) Market?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Non-Small Cell Lung Cancer (NSCLC) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
Browse Through More Reports Similar to the Global Non-Small Cell Lung Cancer (NSCLC) Market 2025, By The Business Research Company
Small Cell Lung Cancer Therapeutics Global Market Report 2025
Urinary Tract Cancer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report
Blockchain Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blockchain-services-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model